HYBRID EVENT: You can participate in person at Germany or Virtually from your home or work.
COPD 2021

Dipankar Bhattacharyya

Dipankar Bhattacharyya, Speaker at Pulmonology Conference
Chichuria Institute of Medical Science & Research, India
Title : Reposition of Montelukast either alone or in combination with Levocetirizine against SARS-CoV-2


It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), anorher two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV. Published in the “Medical Hypotheses (Elsevier), vol. 144, page 110046, Nov 2020”


Dr. Bhattacharyya graduated in Chemistry Honours and post graduated in Biochemistry from Kolkata University. He has completed his Ph.D. In Protein Biochemistry and Enzymology guided by Prof. Parimal C. Sen, Department of Chemistry, Bose Institute and Jadavpur University, Kolkata, India and Postdoctoral training under the supervision of Prof. P.E. Kollatukudy, Department of Molecular Neurobiology, The Ohio State University, Columbus, USA. He has more than 30 years of research and 5 years of teaching experiences in different Universities and Institutes.  Since last 10 years he is working as Principal Investigator from Chichuria Institute of Medical Science and Research, India.